Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Top Cited Papers
Open Access
- 20 September 2012
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 367 (12), 1087-1097
- https://doi.org/10.1056/nejmoa1206328
Abstract
BG-12 (dimethyl fumarate) is in development as an oral treatment for relapsing–remitting multiple sclerosis, which is commonly treated with parenteral agents (interferon or glatiramer acetate).Keywords
This publication has 18 references indexed in Scilit:
- Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 PathwayPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2012
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathwayBrain, 2011
- Dimethyl fumarate for multiple sclerosisExpert Opinion on Investigational Drugs, 2010
- Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1β, TNF-α and IL-6 in an in-vitro model of brain inflammationJournal of Neuroinflammation, 2010
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Annals of Neurology, 2005
- The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapyZeitschrift für Neurologie, 2004
- Placebo‐controlled clinical trials in multiple sclerosis: Ethical considerationsAnnals of Neurology, 2001
- Multiple SclerosisNew England Journal of Medicine, 2000
- Defining the clinical course of multiple sclerosisNeurology, 1996
- Rating neurologic impairment in multiple sclerosisNeurology, 1983